|
|
Volumn 2, Issue 9, 2001, Pages 785-788
|
|
Immunotherapy of multiple sclerosis: Where are we? Where should we go?
a
b
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AUTOANTIGEN;
BETA INTERFERON;
CHEMOKINE;
CYTOKINE;
GLATIRAMER;
HLA DR ANTIGEN;
IMMUNOMODULATING AGENT;
INTERLEUKIN 10;
INTERLEUKIN 12;
INTERLEUKIN 2 RECEPTOR;
INTERLEUKIN RECEPTOR;
MAJOR HISTOCOMPATIBILITY ANTIGEN;
MATRIX METALLOPROTEINASE;
MYELIN;
MYELIN BASIC PROTEIN;
ROQUINIMEX;
T LYMPHOCYTE RECEPTOR;
TRANSFORMING GROWTH FACTOR BETA;
TUMOR NECROSIS FACTOR ALPHA;
TUMOR NECROSIS FACTOR ALPHA RECEPTOR;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANTIINFLAMMATORY ACTIVITY;
AUTOIMMUNE DISEASE;
CONTROLLED STUDY;
DRUG MECHANISM;
DRUG TARGETING;
GENETIC PREDISPOSITION;
HUMAN;
IMMUNOLOGICAL TOLERANCE;
IMMUNOREGULATION;
IMMUNOTHERAPY;
MAJOR HISTOCOMPATIBILITY COMPLEX;
MULTIPLE SCLEROSIS;
NONHUMAN;
NOTE;
PATHOGENESIS;
PRIORITY JOURNAL;
TREATMENT FAILURE;
TREATMENT OUTCOME;
AUTOIMMUNITY;
FORECASTING;
GENETIC PREDISPOSITION TO DISEASE;
HUMANS;
INTERFERON-BETA;
MODELS, IMMUNOLOGICAL;
MULTIPLE SCLEROSIS;
SELF TOLERANCE;
T-LYMPHOCYTES;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 0035554905
PISSN: 15292908
EISSN: None
Source Type: Journal
DOI: 10.1038/ni0901-785 Document Type: Note |
|
Times cited : (68)
|
|
References (23)
|
